卵巢刺激辅助治疗策略在IVF卵巢低反应患者中的系统评价与网状Meta分析
该系统评价与网状Meta分析纳入46项RCT共6312名女性,评估10种辅助治疗对IVF卵巢低反应患者妊娠结局的影响。网状Meta分析纳入19项采用Bologna标准定义POR的RCT共2677名女性。结果显示DHEA和CoQ10可显著提高临床妊娠率,GH、HCG和雌二醇增加获卵数,CoQ10降低周期取消率。
要点
- DHEA和CoQ10辅助治疗可显著提高卵巢低反应患者的临床妊娠几率。
- HCG、雌二醇和GH辅助治疗可增加获卵数,GH还提高HCG日雌二醇水平。
- CoQ10辅助治疗与最低的周期取消率相关。
核心结论
- 对于卵巢低反应患者,采用DHEA、CoQ10和GH辅助治疗的控制性卵巢刺激方案在妊娠结局和促性腺激素用量方面表现更优。
研究设计与样本
- 系统评价与网状Meta分析,检索PubMed、Embase和Cochrane CENTRAL截至2018年7月11日的英文文献。
- 系统评价纳入46项RCT共6312名女性,网状Meta分析纳入19项采用Bologna标准定义POR的RCT共2677名女性。
- 比较10种辅助治疗与对照(单用GnRH类似物和促性腺激素)的妊娠结局,方案注册于PROSPERO(CRD42018086217)。
主要发现
- 与对照相比,DHEA和CoQ10辅助治疗显著提高临床妊娠率(OR 2.46,95%CI 1.16-5.23;OR 2.22,95%CI 1.08-4.58)。
- 与对照相比,HCG、雌二醇和GH辅助治疗的获卵数最高(WMD 2.08,95%CI 0.72-3.44;WMD 2.02,95%CI 0.23-3.81;WMD 1.72,95%CI 0.98-2.46)。
- 与对照相比,睾酮和GH辅助治疗的移植胚胎数最高(WMD 0.72,95%CI 0.11-1.33;WMD 0.67,95%CI 0.43-0.92)。
- 与对照相比,GH辅助治疗的HCG日雌二醇水平最高(WMD 797.63,95%CI 466.45-1128.81)。
- 与对照相比,克罗米芬、来曲唑和GH组的促性腺激素用量最低(WMD -1760.00,95%CI -2890.55至-629.45;WMD -1110.17,95%CI -1753.37至-466.96;WMD -875.91,95%CI -1433.29至-282.52),CoQ10组周期取消率最低(OR 0.33,95%CI 0.15-0.74)。
临床怎么用
- 对于卵巢低反应患者,可考虑在控制性卵巢刺激中辅以DHEA、CoQ10或GH以改善妊娠结局并减少促性腺激素用量。
局限性
- 未来需纳入采用统一POR标准的高质量RCT进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite great advances in assisted reproductive technology, poor ovarian response (POR) is still considered as one of the most challenging tasks in reproductive medicine. OBJECTIVE AND RATIONALE: The aim of this systemic review is to evaluate the role of different adjuvant treatment strategies on the probability of pregnancy achievement in poor responders undergoing IVF. Randomized controlled trials (RCTs) comparing 10 adjuvant treatments [testosterone, dehydroepiandrosterone (DHEA), letrozole, recombinant LH, recombinant hCG, oestradiol, clomiphene citrate, progesterone, growth hormone (GH) and coenzyme Q10 (CoQ10)] were included. SEARCH METHODS: Relevant studies published in the English language were comprehensively selected using PubMed, Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) until 11 July 2018. We included studies that investigated various adjuvant agents, including androgen and androgen-modulating agents, oestrogen, progesterone, clomiphene citrate, GH and CoQ10, during IVF treatment and reported subsequent pregnancy outcomes. The administration of GnRH analogs and gonadotrophins without adjuvant treatment was set as the control. We measured study quality based on the methodology and categories listed in the Cochrane Collaboration Handbook. This review protocol was registered with PROSPERO (CRD42018086217). OUTCOMES: Of the 1124 studies initially identified, 46 trials reporting on 6312 women were included in this systematic review, while 19 trials defining POR using the Bologna criteria reporting 2677 women were included in the network meta-analysis. Compared with controls, DHEA and CoQ10 treatments resulted in a significantly higher chance of clinical pregnancy [odds ratio (OR) 2.46, 95% CI 1.16 to 5.23; 2.22, 1.08-4.58, respectively]. With regard to the number of retrieved oocytes, HCG, oestradiol and GH treatments had the highest number of oocytes retrieved [weighted mean difference (WMD) 2.08, 0.72 to 3.44; 2.02, 0.23 to 3.81; 1.72, 0.98 to 2.46, compared with controls, respectively]. With regard to the number of embryos transferred, testosterone and GH treatment led to the highest number of embryos transferred (WMD 0.72, 0.11 to 1.33; 0.67, 0.43 to 0.92; compared with controls, respectively). Moreover, GH resulted in the highest oestradiol level on the HCG day (WMD 797.63, 466.45 to 1128.81, compared with controls). Clomiphene citrate, letrozole and GH groups used the lowest dosages of gonadotrophins for ovarian stimulation (WMD 1760.00, -2890.55 to -629.45; -1110.17, -1753.37 to -466.96; -875.91, -1433.29 to -282.52; compared with controls, respectively). CoQ10 led to the lowest global cancelation rate (OR 0.33, 0.15 to 0.74, compared with controls). WIDER IMPLICATIONS: For patients with POR, controlled ovarian stimulation protocols using adjuvant treatment with DHEA, CoQ10 and GH showed better clinical outcomes in terms of achieving pregnancy, and a lower dosage of gonadotrophin required for ovulation induction. Furthermore, high-level RCT studies using uniform standards for POR need to be incorporated into future meta-analyses.
引用
- Zhang Y, Zhang C, Shu J, et al. Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. Hum Reprod Update. 2020. PMID: 32045470. doi:10.1093/humupd/dmz046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。